Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

NCT05980416 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

88

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Stomach Neoplasm
Gastrointestinal Neoplasms
Digestive System Neoplasm
Neoplasms by Site
Neoplasms

Interventions

DRUG: EO-3021
DRUG: Ramucirumab (CYRAMZA®)
DRUG: Dostarlimab

Sponsor

Elevation Oncology

Collaborators

[object Object]
[object Object]
[object Object]